标题
FGF Receptor Inhibitors: Role in Cancer Therapy
作者
关键词
-
出版物
Current Oncology Reports
Volume 14, Issue 2, Pages 111-119
出版商
Springer Nature
发表日期
2012-02-04
DOI
10.1007/s11912-012-0225-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
- (2011) M. Reck et al. ANNALS OF ONCOLOGY
- Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure
- (2011) Koichi Azuma et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2011) J.-W. Park et al. CLINICAL CANCER RESEARCH
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma
- (2011) K. B. Kim et al. CLINICAL CANCER RESEARCH
- Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
- (2011) Elizabeth Allen et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of telomerase activity by HDV ribozyme in cancers
- (2011) Yingying Lu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
- (2011) Vito Guagnano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Multikinase inhibitors: a new option for the treatment of thyroid cancer
- (2011) Matti L. Gild et al. Nature Reviews Endocrinology
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
- (2010) D. J. Jonker et al. ANNALS OF ONCOLOGY
- Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration
- (2010) G Sonvilla et al. BRITISH JOURNAL OF CANCER
- Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors
- (2010) Haruyasu Murakami et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors
- (2010) Yutaka Ueda et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma
- (2010) Fumihiko Kanai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Regulation of the expression balance of angiopoietin-1 and angiopoietin-2 by Shh and FGF-2
- (2010) Takaaki Fujii et al. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
- A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
- (2010) Ron J. Keizer et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2010) I. Okamoto et al. MOLECULAR CANCER THERAPEUTICS
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
- (2009) A. du Bois et al. ANNALS OF ONCOLOGY
- Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
- (2009) K. Mross et al. CLINICAL CANCER RESEARCH
- Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development
- (2009) Edoardo Missiaglia et al. GENES CHROMOSOMES & CANCER
- Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
- (2009) Jing Qing et al. JOURNAL OF CLINICAL INVESTIGATION
- Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation
- (2009) S. Kang et al. MOLECULAR AND CELLULAR BIOLOGY
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner
- (2009) E di Martino et al. ONCOGENE
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- (2009) Patrice Dubreuil et al. PLoS One
- FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
- (2008) K. Kunii et al. CANCER RESEARCH
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2008) D. Sarker et al. CLINICAL CANCER RESEARCH
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting
- (2008) Kristian Pietras et al. PLOS MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now